UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 241

Sortiert nach

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors

Japanese journal of clinical oncology, 2020-08, Vol.50 (8), p.859-866

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers

Clinical and translational science, 2020-03, Vol.13 (2), p.325-336

2020

Link zum Volltext

Verfügbarkeit prüfen

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

CPT: pharmacometrics and systems pharmacology, 2021-05, Vol.10 (5), p.428-440

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study

Clinical and translational science, 2022-08, Vol.15 (8), p.1990-1998

2022

Link zum Volltext

Verfügbarkeit prüfen

Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene

Clinical pharmacology and therapeutics, 2002-11, Vol.72 (5), p.584-594

2002

Link zum Volltext

Verfügbarkeit prüfen

Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21057-e21057

2023

Link zum Volltext

Verfügbarkeit prüfen

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

Molecular cancer therapeutics, 2023-07, Vol.22 (7), p.833-843

2023

Link zum Volltext

Verfügbarkeit prüfen

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

The New England journal of medicine, 2020-09, Vol.383 (10), p.931-943

2020

Link zum Volltext

Verfügbarkeit prüfen

Absolute Bioavailability and Effect of Food on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects

Clinical pharmacology in drug development, 2013-01, Vol.2 (1), p.79-89

2013

Link zum Volltext

Verfügbarkeit prüfen

A Single Nucleotide Polymorphism in the Human H-ras Proto-oncogene Determines the Risk of Urinary Bladder Cancer

Cancer epidemiology, biomarkers & prevention, 2003-01, Vol.12 (1), p.68-70

2003

Link zum Volltext

Verfügbarkeit prüfen

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Clinical cancer research, 2020-03, Vol.26 (6), p.1237-1246

2020

Link zum Volltext

Verfügbarkeit prüfen

Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors

Drug metabolism and disposition, 2017-02, Vol.45 (2), p.174-182

2017

Link zum Volltext

Verfügbarkeit prüfen

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

Investigational new drugs, 2020-10, Vol.38 (5), p.1507-1519

2020

Link zum Volltext

Verfügbarkeit prüfen

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

The lancet respiratory medicine, 2020-11, Vol.8 (11), p.1132-1143

2020

Link zum Volltext

Verfügbarkeit prüfen

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

Cancer chemotherapy and pharmacology, 2022-07, Vol.90 (1), p.53-69

2022

Link zum Volltext

Verfügbarkeit prüfen

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients

British journal of clinical pharmacology, 2016-12, Vol.82 (6), p.1498-1508

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Clinical cancer research, 2023-05, Vol.29 (10), p.1879-1886

2023

Link zum Volltext

Verfügbarkeit prüfen

Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study

Cancer science, 2024-04, Vol.115 (4), p.1296-1305

2024

Link zum Volltext

Verfügbarkeit prüfen

PP01.83 Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e37-e38

2024

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION

British journal of cancer, 2024-06, Vol.130 (10), p.1679-1686

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification ( MET amp) detected by liquid biopsy (LBx)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9121-9121

2022

Link zum Volltext

Verfügbarkeit prüfen

Evidence for Inverse Effects of OATP‐C (SLC21A6) 5 and 1b Haplotypes on Pravastatin Kinetics

Clinical pharmacology and therapeutics, 2004-05, Vol.75 (5), p.415-421

2004

Link zum Volltext

Verfügbarkeit prüfen

Influence of the SLCO1B11b and 5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels

Naunyn-Schmiedeberg's archives of pharmacology, 2006-04, Vol.373 (1), p.45-50

2006

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9060-9060

2023

Link zum Volltext

Verfügbarkeit prüfen

PPD01.01 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION Trial

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e4-e4

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 241

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(232)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(51)
Humans
(39)
Male
(30)
Adult
(24)
Female
(23)
Pharmacology & Pharmacy
(23)
Middle Aged
(18)
Biological And Medical Sciences
(16)
Medical Sciences
(15)
Aged
(14)
Pharmacology. Drug Treatments
(13)
Oncology
(12)
Pharmacokinetics
(11)
Drug Interactions
(9)
Animals
(8)
Aged, 80 And Over
(7)
Area Under Curve
(7)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)
Genotype
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study

Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene

Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Absolute Bioavailability and Effect of Food on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects

A Single Nucleotide Polymorphism in the Human H-ras Proto-oncogene Determines the Risk of Urinary Bladder Cancer

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study

PP01.83 Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC

Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION

Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification ( MET amp) detected by liquid biopsy (LBx)

Evidence for Inverse Effects of OATP‐C (SLC21A6) 5 and 1b Haplotypes on Pravastatin Kinetics

Influence of the SLCO1B11b and 5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels

Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study

PPD01.01 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION Trial

Suchergebnisse filtern